nafamostat has been researched along with Cancer of Liver in 6 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Excerpt | Relevance | Reference |
---|---|---|
"To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 8.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
"Nafamostat mesilate is an anti-inflammatory drug that is usually used to treat pancreatitis." | 5.43 | Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. ( Chen, G; Chen, LZ; Ju, HQ; Kang, TB; Lu, YX; Mo, HY; Pan, ZZ; Sheng, H; Wang, F; Wu, QN; Xie, D; Xu, RH; Yun, JP; Zeng, ZL, 2016) |
"To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 4.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
"The effect of nafamostat mesilate on coagulation and fibrinolysis was investigated in a study of 22 patients with hepatocellular carcinoma who underwent a hepatic resection." | 3.69 | Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection. ( Kamakura, T; Matsumata, T; Shimada, M; Shirabe, K; Sugimachi, K; Taketomi, A, 1994) |
" Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, inhibited liver metastasis in a CDF1 mice model with colon 26 adenocarcinoma cells." | 3.68 | Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. ( Fuchimoto, S; Hizuta, A; Iwagaki, H; Kimura, T; Orita, K, 1992) |
"Nafamostat mesilate is an anti-inflammatory drug that is usually used to treat pancreatitis." | 1.43 | Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis. ( Chen, G; Chen, LZ; Ju, HQ; Kang, TB; Lu, YX; Mo, HY; Pan, ZZ; Sheng, H; Wang, F; Wu, QN; Xie, D; Xu, RH; Yun, JP; Zeng, ZL, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Lee, B | 1 |
Cho, JY | 1 |
Han, HS | 1 |
Yoon, YS | 1 |
Lee, HW | 1 |
Lee, JS | 1 |
Kim, M | 1 |
Jo, Y | 1 |
Saito, N | 1 |
Uwagawa, T | 1 |
Hamura, R | 1 |
Takada, N | 1 |
Sugano, H | 1 |
Shirai, Y | 1 |
Shiba, H | 1 |
Ohashi, T | 1 |
Yanaga, K | 1 |
Lu, YX | 1 |
Ju, HQ | 1 |
Wang, F | 1 |
Chen, LZ | 1 |
Wu, QN | 1 |
Sheng, H | 1 |
Mo, HY | 1 |
Pan, ZZ | 1 |
Xie, D | 1 |
Kang, TB | 1 |
Chen, G | 1 |
Yun, JP | 1 |
Zeng, ZL | 1 |
Xu, RH | 1 |
Shimada, M | 1 |
Matsumata, T | 1 |
Shirabe, K | 1 |
Kamakura, T | 1 |
Taketomi, A | 1 |
Sugimachi, K | 1 |
Suzuki, H | 1 |
Nimura, Y | 1 |
Kamiya, J | 1 |
Kondo, S | 1 |
Nagino, M | 1 |
Kanai, M | 1 |
Miyachi, M | 1 |
Kimura, T | 1 |
Fuchimoto, S | 1 |
Iwagaki, H | 1 |
Hizuta, A | 1 |
Orita, K | 1 |
1 review available for nafamostat and Cancer of Liver
Article | Year |
---|---|
Preoperative transcatheter arterial embolization for giant cavernous hemangioma of the liver with consumption coagulopathy.
Topics: Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Disseminated Intravascular Coagulati | 1997 |
5 other studies available for nafamostat and Cancer of Liver
Article | Year |
---|---|
Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Benzamidines; Bilirubin; Carcinoma, Hepatocellula | 2022 |
Prevention of early liver metastasis after pancreatectomy by perioperative administration of a nuclear factor-κB inhibitor in mice.
Topics: Animals; Benzamidines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; | 2019 |
Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Cell Movement; Cel | 2016 |
Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
Topics: Aged; Antifibrinolytic Agents; Benzamidines; Blood Coagulation; Blood Loss, Surgical; Carcinoma, Hep | 1994 |
Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antithrombins; Benzamidines; Colonic Neoplasms; Extr | 1992 |